Effective, rapid control of active pemphigus is achievable with intravenous immunoglobulin when conventional therapy fails. American researchers suggest it acts by decreasing serum levels of intercellular antibodies.
Researchers at New York University School of Medicine, in New York, United States, re-examined the effectiveness of intravenous immunoglobulin (IVIg) for the immediate control of active pemphigus. It followed previously published conflicting studies on the recently advocated therapy.
Six patients with active pemphigus vulgaris were enrolled in the study.
Conventional dermatological treatment with high doses of corticosteroids had failed. They were each given IVIg (400-mg/kg daily) over five days and concurrently received cyclophosphamide 100-150mg/ per day. Primary end points were healing of skin lesions and changes in the level of intercellular antibodies and steroid dose. Within a week of commencing intravenous immunoglobulin therapy, new lesions were no longer forming.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!